StageZero Life Sciences Ltd. (SZLSF)
- Previous Close
0.0000 - Open
0.0605 - Bid 0.0017 x --
- Ask 0.2400 x --
- Day's Range
0.0605 - 0.0605 - 52 Week Range
0.0015 - 0.9999 - Volume
300 - Avg. Volume
2,522 - Market Cap (intraday)
3.63M - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date Nov 18, 2024 - Nov 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
www.stagezerolifesciences.com40
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SZLSF
View MorePerformance Overview: SZLSF
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SZLSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SZLSF
View MoreValuation Measures
Market Cap
3.01M
Enterprise Value
5.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.93
Price/Book (mrq)
--
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.80%
Return on Equity (ttm)
--
Revenue (ttm)
2.98M
Net Income Avi to Common (ttm)
-12.53M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
20.72k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.18M